Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLLUX: Daratumumab + Lenalidomide + Dexamethasone in RRMM
NCT02076009Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2014
- Primary completion
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of daratumumab in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free Survival up to 21 months. Started Jul 2014; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02076009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076009.